9911796707
|
Home
Issues:
Import of bulk drugs for manufacturing, benefit of Customs duty under Notification No. 17/2001-CUS, compliance with Customs (Import of Goods at Concessional rate of duty for manufacture of Excisable Goods) Rules, 1996, eligibility of importers for benefit, manufacturer's undertaking, denial of benefit by Customs authorities, interpretation of Notification provisions. Analysis: The case involved the import of bulk drugs by the appellants at the port of Mumbai for manufacturing purposes under a loan license arrangement with M/s. Savill Pharma Labs Pvt. Ltd. The appellants sought the benefit of Customs duty under Notification No. 17/2001-CUS, Serial No. 81. The Customs authorities denied the benefit, contending that the manufacturer had to be the importer, M/s. FDC, who did not provide the necessary undertaking as per the Customs (Import of Goods at Concessional rate of duty for manufacture of Excisable Goods) Rules, 1996. The Tribunal, comprising S/Shri S.S. Sekhon and Krishna Kumar, analyzed the situation and observed that the benefit of the Notification pertained to the goods themselves and not specifically to the importer-manufacturer. Since the bulk drugs were being manufactured at M/s. Savill Pharma Labs in compliance with the prescribed procedures and rules, the Tribunal found no valid reasons to support the duty demand or the denial of the Notification benefit at the prima facie stage. As a result of their analysis, the Tribunal granted a full waiver and stay of the duty amount pending the regular hearing of the appeal. The application was disposed of with the aforementioned terms, emphasizing the importance of adherence to the prescribed rules and procedures for availing the benefits under the Notification. The judgment highlights the significance of fulfilling the conditions specified in the Customs rules to qualify for duty concessions and the need for a comprehensive understanding of the legal provisions governing such import scenarios.
|
